Citation Impact
Citing Papers
Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial
2009
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
2011 Standout
Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study
2010
Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma
2010
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
2015 Standout
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Beyond Antibodies: The DARPin® Drug Platform
2020
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma
2012
The role of P-glycoprotein in drug resistance in multiple myeloma
2014
The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy
2015 Standout
Non‐genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report
2010
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
2009 Standout
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Non-Transgenic Mouse Models of Kidney Disease
2016 Standout
Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD‐2076, against multiple myeloma
2010
Basic aspects of inhibitors to factors VIII and IX and the influence of non‐genetic risk factors
2006
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
2018 StandoutNobel
Prevention of VTE in Nonsurgical Patients
2012 Standout
Network meta‐analysis of parametric survival curves
2010
Cellular senescence in ageing: from mechanisms to therapeutic opportunities
2020 Standout
Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients
2009
Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β-Induced Interleukin 6 Production and the Myeloma Proliferative Component
2009
Immunity, Inflammation, and Cancer
2010 Standout
Systemic amyloidosis
2015 Standout
Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation
2011
Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
2012 Standout
The use of novel agents in the treatment of relapsed and refractory multiple myeloma
2009
Pathogenesis and treatment of renal failure in multiple myeloma
2008
Pegylated Liposomal Doxorubicin
2008
Thalidomide suppresses inflammation in adenine-induced CKD with uraemia in mice
2013
De novo design of buttressed loops for sculpting protein functions
2024 StandoutNobel
Infections in Patients with Multiple Myeloma in the Era of High‐Dose Therapy and Novel Agents
2009
Targeting DNA topoisomerase II in cancer chemotherapy
2009 Standout
Postallograft lenalidomide induces strong NK cell–mediated antimyeloma activity and risk for T cell–mediated GvHD: Results from a phase I/II dose-finding study
2012
Proteasome Inhibitors with Photocontrolled Activity
2014 StandoutNobel
DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
2010 Standout
High-Dose Treatment With Autologous Stem Cell Transplantation in Multiple Myeloma: Past, Present, and Future
2007
Targeting Immune Checkpoints in Hematologic Malignancies
2016
Treatment of Multiple Myeloma: A Comprehensive Review
2009
Discovery and resupply of pharmacologically active plant-derived natural products: A review
2015 Standout
Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma
2010
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
2012
Biological Activity of Lenalidomide and Its Underlying Therapeutic Effects in Multiple Myeloma
2012
A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis
2012
Fundamentals of cancer metabolism
2016 Standout
Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial
2010
DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition
2009 Standout
Safety, Pharmacokinetics, and Immunomodulatory Effects of Lenalidomide in Children and Adolescents With Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome: A Children's Oncology Group Phase I Consortium Report
2010
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies
2017 StandoutNobel
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
2014
Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study
2010
Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents
2008
The emerging role of immune checkpoint based approaches in AML and MDS
2017 StandoutNobel
The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma
2014
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
2009
Natural product and natural product derived drugs in clinical trials
2014 Standout
How I treat multiple myeloma in younger patients
2009
Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application
2018 Standout
Natural Products as Sources of New Drugs from 1981 to 2014
2016 Standout
Anticoagulation for people with cancer and central venous catheters
2014
Multiple Myeloma
2011 Standout
ATM-ATR–dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype
2008
Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
2012 Standout
A Comprehensive Review on Medicinal Plants as Antimicrobial Therapeutics: Potential Avenues of Biocompatible Drug Discovery
2019 Standout
Structural Basis of Type II Topoisomerase Inhibition by the Anticancer Drug Etoposide
2011 StandoutScience
Guidelines for the management of hemophilia
2012 Standout
Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma
2017
Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
2009
Anthraquinones As Pharmacological Tools and Drugs
2016 Standout
Works of Sara Bringhen being referenced
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
2008
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study
2013
TWO DOSE-INTENIVE MELPHALAN REGIMENS (100 MG/M2 VERSUS 200 MG/M2) IN MULTIPLE MYELOMA PATIENTS
2003
Time to first disease progression, but not β2‐microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy
2007
Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients
2011
The mechanism of action, pharmacokinetics, and clinical efficacy of carfilzomib for the treatment of multiple myeloma
2013
Melphalan and its role in the management of patients with multiple myeloma
2007
Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma
2012
A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma
2007
Intermediate-Dose Melphalan (100 mg/m2)/Bortezomib/Thalidomide/Dexamethasone and Stem Cell Support in Patients with Refractory or Relapsed Myeloma
2006
Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma
2013
Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients
2010
A Phase III Study of Enoxaparin Versus Low-Dose Warfarin Versus Aspirin as Thromboprophylaxis for Patients with Newly Diagnosed Multiple Myeloma Treated up-Front with Thalidomide-Containing Regimens
2008
Final Analysis of a Multicenter, Randomised Study Comparing Zoledronate vs Observation in Patients with Asymptomatic Myeloma.
2007
Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma
2006
Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma
2008
The MP0250-CP201 Mirror Study: A Phase 2 Study Update of MP0250 Plus Bortezomib and Dexamethasone in Relapse/Refractory Multiple Myeloma (RRMM) Patients Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs
2019
Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA—Italian Multiple Myeloma Network
2007